Sentences with phrase «develop over time due»

These injuries may happen suddenly after bending over to pick up one item, or they may develop over time due to repeated bending.

Such effects can occur years later, after just a single or short - term exposure, or can develop over time due to repeated exposure to pollutants.

The human species is essentially homogeneous from a genetic perspective, however, the various groups have some subtle but significant differences at statistical and scientific level that have developed over time due to the effect of geographical, demographic and cultural factors» says Valentina Coia.

This research indicates that drug resistance develops over time due to the biofilm development.

As discussed in Part I of the Sock Doc First Aid For Injuries, if you didn't have some sort of traumatic accident then your injury was slowly developing over time due to muscle imbalances which resulted from too...

Not exact matches

Actual results, including with respect to our targets and prospects, could differ materially due to a number of factors, including the risk that we may not obtain sufficient orders to achieve our targeted revenues; price competition in key markets; the risk that we or our channel partners are not able to develop and expand customer bases and accurately anticipate demand from end customers, which can result in increased inventory and reduced orders as we experience wide fluctuations in supply and demand; the risk that our commercial Lighting Products results will continue to suffer if new issues arise regarding issues related to product quality for this business; the risk that we may experience production difficulties that preclude us from shipping sufficient quantities to meet customer orders or that result in higher production costs and lower margins; our ability to lower costs; the risk that our results will suffer if we are unable to balance fluctuations in customer demand and capacity, including bringing on additional capacity on a timely basis to meet customer demand; the risk that longer manufacturing lead times may cause customers to fulfill their orders with a competitor's products instead; the risk that the economic and political uncertainty caused by the proposed tariffs by the United States on Chinese goods, and any corresponding Chinese tariffs in response, may negatively impact demand for our products; product mix; risks associated with the ramp - up of production of our new products, and our entry into new business channels different from those in which we have historically operated; the risk that customers do not maintain their favorable perception of our brand and products, resulting in lower demand for our products; the risk that our products fail to perform or fail to meet customer requirements or expectations, resulting in significant additional costs, including costs associated with warranty returns or the potential recall of our products; ongoing uncertainty in global economic conditions, infrastructure development or customer demand that could negatively affect product demand, collectability of receivables and other related matters as consumers and businesses may defer purchases or payments, or default on payments; risks resulting from the concentration of our business among few customers, including the risk that customers may reduce or cancel orders or fail to honor purchase commitments; the risk that we are not able to enter into acceptable contractual arrangements with the significant customers of the acquired Infineon RF Power business or otherwise not fully realize anticipated benefits of the transaction; the risk that retail customers may alter promotional pricing, increase promotion of a competitor's products over our products or reduce their inventory levels, all of which could negatively affect product demand; the risk that our investments may experience periods of significant stock price volatility causing us to recognize fair value losses on our investment; the risk posed by managing an increasingly complex supply chain that has the ability to supply a sufficient quantity of raw materials, subsystems and finished products with the required specifications and quality; the risk we may be required to record a significant charge to earnings if our goodwill or amortizable assets become impaired; risks relating to confidential information theft or misuse, including through cyber-attacks or cyber intrusion; our ability to complete development and commercialization of products under development, such as our pipeline of Wolfspeed products, improved LED chips, LED components, and LED lighting products risks related to our multi-year warranty periods for LED lighting products; risks associated with acquisitions, divestitures, joint ventures or investments generally; the rapid development of new technology and competing products that may impair demand or render our products obsolete; the potential lack of customer acceptance for our products; risks associated with ongoing litigation; and other factors discussed in our filings with the Securities and Exchange Commission (SEC), including our report on Form 10 - K for the fiscal year ended June 25, 2017, and subsequent reports filed with the SEC.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The value I was assigned by my peers due to my otherness developed over time and changed depending on age and environment.

Plus if you play Rosicky over let's say Wilshere, then Wilshere is less able to develop and progress as a player due to a lack of game time.

«Changes due to osteoarthritis, such as narrowing in the space between joints and the development of bony proliferations, typically develop slowly over time,» said Connie Y. Chang, M.D., radiologist at Massachusetts General Hospital and assistant professor of radiology at Harvard Medical School in Boston.

Also, because HD takes many years or decades to develop, differences seen in HD patients may seem large at the baseline but actually be due to very slow changes that take place over a long time.

With PCOS, women can develop «cysts» due to eggs not being released over time.

The partnership is set up by Captain Maldonado, a tough but sensible authority type who, due to the presence of talented actress Lili Taylor, will likely develop more dimension over time.

A Sundance personality who over time, has developed his own cult following in large part due to the exposure received in Park City.

While we have no idea where oil prices will settle in the short run, it remains our view that oil prices can not stay down at today's depressed prices for too long, largely due to what we believe to be the relatively modest current level of excess capacity, our expectations of continued growth in demand over time, and the high marginal costs for finding and developing new sources of supply.

Chicken appears as the primary protein source in so many dog foods that over time your dog could develop an allergy purely due to overexposure.

Her compression (or herniation) was not due to an injury either, it was most likely a condition that developed slowly over time because of a weakness in the disc.

What makes parasites a challenge is that many different types of parasites develop resistance to chemicals over time due to the process of natural selection.

Wherein in the former the joints have not developed appropriately due to numerous reasons and cause hip or elbow dysplasia, the latter is the reason dogs suffer from arthritis in which the ligaments degenerate over a period of time leading to shakiness and secondary osteoarthritis.

These are among several possibilities that scientists from all over the world grapple with as they attempt to develop a regional climate model for Sunderbans that can predict different scenarios at a time when the mangrove delta is being battered by cyclones and getting inundated due to sea - level rise.

We updated version A after discovering that the eastward drift of NOAA - 11 over its 6 - yr life span caused a spurious warming effect to develop due, as we believed, to the fact the satellite was sampling the earth at later times during the local diurnal cycle (version B, Christy et al. 1995).»

These arteries may be narrowed due to blockages or clogging by a buildup of plaque or fatty deposits that develop over time.

We also understand, due to our nature, all relationships develop over time.